Shares of Stemline Therapeutics Inc (NASDAQ:STML) hit a new 52-week high during trading on Thursday . The stock traded as high as $17.60 and last traded at $16.55, with a volume of 346200 shares traded. The stock had previously closed at $16.55.
Several brokerages have recently commented on STML. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Stemline Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $33.75.
The firm has a market capitalization of $514.25, a PE ratio of -6.91 and a beta of -0.02.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC acquired a new stake in Stemline Therapeutics during the second quarter valued at $102,000. Royce & Associates LP acquired a new stake in Stemline Therapeutics during the fourth quarter valued at $106,000. Nationwide Fund Advisors boosted its position in Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 855 shares during the last quarter. Two Sigma Investments LP acquired a new stake in Stemline Therapeutics during the fourth quarter valued at $170,000. Finally, Alliancebernstein L.P. acquired a new stake in Stemline Therapeutics during the second quarter valued at $178,000. 42.52% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2018/02/24/stemline-therapeutics-stml-hits-new-12-month-high-at-17-60.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.